




Appl. Sci. 2021, 11, 925. https://doi.org/10.3390/app11030925 www.mdpi.com/journal/applsci 
Article 
Development of a Biodegradable Microcarrier for the  
Cultivation of Human Adipose Stem Cells (hASCs) with a  
Defined Xeno- and Serum-Free Medium 
Francesco Muoio 1,†, Stefano Panella 1,†, Matias Lindner 2,†, Valentin Jossen 3,†, Yves Harder 4,5, Tiziano Moccetti 1, 
Regine Eibl 3,‡, Michele Müller 2,‡ and Tiziano Tallone 1,*,‡ 
1 Foundation for Cardiological Research and Education (FCRE), Cardiocentro Ticino Foundation,  
6807 Taverne, Switzerland; francesco.muoio@cardiocentro.org (F.M.);  
stefano.panella@cardiocentro.org (S.P.); tiziano.moccetti@cardiocentro.org (T.M.) 
2 Sferalp SA, 6998 Monteggio, Switzerland; mlin@sferalp.com (M.L.); mmul@sferalp.com (M.M.) 
3 Institute of Chemistry and Biotechnology, Competence Center of Biochemical Engineering and Cell Cultiva-
tion Technique Zurich University of Applied Sciences, 8820 Wädenswil, Switzerland; jose@zhaw.ch (V.J.); 
eibs@zhaw.ch (R.E.) 
4 Department of Plastic, Reconstructive and Aesthetic Surgery, EOC, 6900 Lugano, Switzerland; 
yves.harder@eoc.ch or yves.harder@usi.ch 
5 Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland 
* Correspondence: tiziano.tallone@cardiocentro.org; Tel.: +41-91-805-38-85 
† These authors contributed equally to this study (co-first author). 
‡ These authors supervised this study equally. 
Abstract: Stirred single-use bioreactors in combination with microcarriers (MCs) have established 
themselves as a technology that has the potential to meet the demands of current and future cell 
therapeutic markets. However, most of the published processes have been performed using fetal 
bovine serum (FBS) containing cell culture medium and non-biocompatible MCs. This approach 
has two significant drawbacks: firstly, the inevitable potential risks associated with the use of FBS 
for clinical applications; secondly, non-biocompatible MCs have to be removed from the cell sus-
pension before implantation, requiring a step that causes loss of viable cells and adds further costs 
and complications. This study aimed to develop a new platform based on a chemically defined 
xeno- and serum-free cell culture medium and biodegradable MC that can support the growth of 
human adipose stem cells (hASCs) while still preserving their undifferentiated status. A specific 
combination of components and manufacturing parameters resulted in a MC prototype, called 
“BR44”, which delivered the desired functionality. MC BR44 allows the hASCs to stick to its surface 
and grow in a chemically defined xeno- and serum-free medium (UrSuppe). Although the cells’ ex-
pansion rate was not as high as with a commercial non-biodegradable standard MC, those cultured 
on BR44 maintained a better undifferentiated status in both static and dynamic conditions than 
those cultured on traditional 2D surfaces. 
Keywords: xeno- and serum-free cell culture medium; UrSuppe; bioresorbable/biodegradable mi-
crocarrier (MC), human adipose stem cells (hASCs) 
 
1. Introduction 
Adipose tissue has become one of the most promising cell sources for regenerative 
medicine since it is easily accessible. It is an abundant source of adult stem cells that can 
differentiate along multiple pathways [1–3]. This makes definitively human Adipose 
Stem Cells (hASCs) a major candidate for tissue engineering applications. They are also 
increasingly used in plastic and reconstructive surgical procedures, where a shift toward 
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tissue-engineering strategies using stem cells [4–6] is apparent. However, due to the lim-
ited number of stem cells that can be extracted from a single donor, one of the major chal-
lenges for the field of bioengineering is the development of production processes that are 
both compliant with Good Manufacturing Practice (GMP) guidelines and able to generate 
a high amount of safe stem cells in a reproducible and cost-effective way [7,8]. This latter 
aspect, namely the manufacturing costs of cell therapeutics, presents a significant barrier 
to the widespread implementation of stem cell-based therapies. More specifically, when 
examining the overall fabrication process, cell expansion represents one of the main cost 
drivers for cell therapeutics production [8]. 
One major obstacle is the limited availability of clinical-grade reagents for use in an-
cillary materials (AMs) [9]. Consequently, it would be essential to develop some of the 
most crucial AMs needed to manufacture cell therapy products. Therefore, using a de-
fined xeno- and serum-free medium and the development of a biodegradable microcarrier 
(MC) to produce high numbers of hASCs will represent a step towards the resolution of 
this issue. 
Fetal bovine serum (FBS) is still the most used cell culture medium supplement, alt-
hough it is an undefined cocktail of numerous growth factors and hormones. This ancil-
lary material is unsafe and risky because it may contain harmful contaminants such as 
prion, viral, or zoonotic agents [10]. Moreover, human primary progenitor cells grown in 
FBS-containing media become associated with FBS proteins [11], which may cause im-
mune xenogenic rejection upon autologous transplantation in patients, particularly when 
multiple doses are required. 
Furthermore, tissue (stem) cells usually are never in contact with serum but in contact 
with the interstitial fluid, which has a lower concentration of proteins than serum and is 
specific for each tissue or organ due to the unique composition of secreted polypeptides 
and metabolic molecules [12,13]. This is a situation that we can try to reproduce and mimic 
by using defined serum-free conditions. Finally, there are also serious ethical concerns 
about FBS’ use regarding its harvesting and production process, without forgetting the 
risk of adulterated composition and unstable prices. 
Biodegradable and biocompatible microspheres are a continuing focus of research 
for their numerous applications in biomedicine and biotechnology, including immobili-
zation [14,15], affinity chromatography [16,17], drug delivery [18,19], and MCs for the cul-
tivation of anchorage-dependent cells [20–22]. MCs have established themselves as a 
promising technology for meeting current and future cell therapeutic markets’ demands 
combined with stirred single-use bioreactors. MC technology provides a large culture sur-
face in a small volume for the cost-effective production of adherent cells. It enables repro-
ducible Good Manufacturing Practice (GMP) compliant cell expansions in closed, con-
trolled, and scalable processes [7,23]. A common approach in tissue engineering is to har-
vest the cells from their growth surface and inject them intravenously. However, for spe-
cific applications (such as bone and cartilage repair), there is a need to seed the cells on a 
scaffold that serves as a substrate and temporary matrix, which can be inserted into the 
defect to stimulate tissue regeneration. This approach is more time-consuming because it 
involves three steps: (I) cell expansion in a dedicated system, (II) cell harvesting, and (III) 
seeding onto a scaffold before implantation. Traditional enzymatic dissociation methods 
using proteases (i.e., Trypsin) are the most common cell harvesting methods. However, 
they only result in a 60%–70% cell recovery, depending on the MCs properties. The enzy-
matic process may also cause reduced cell viability and high apoptotic activity, limiting 
the transplanted cells’ therapeutic efficacy. Therefore, biodegradable MCs are advanta-
geous, as cell harvest or use of new scaffolds is not necessary for cell transfer [24]. In this 
manner, high cell viability and potency can be maintained. 
This feasibility study’s product is a porous poly(D,L-lactide-co-glycolide) (PLGA) 
based MC (called BR44), manufactured as a microsphere with physically embedded por-
cine gelatin, a natural polymer already approved for clinical use [25]. Due to the adverse 
effects of FBS in clinical applications [11,26,27], the MC was used with proprietary defined 
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xeno- and serum-free cell culture medium (UrSuppe) suitable for the dynamic cultivation 
of hASCs in stirred single-use bioreactors. We think that this approach of developing a 
biodegradable MC combined with a serum-free medium to grow hASCs is very appropri-
ate; since it has recently been shown that compatible serum-free media is cell-specific and 
requires optimization for MC-based dynamic cell culture systems [28]. To our knowledge, 
only three biodegradable MCs are commercially and readily available: Fujifilm’s Cellnest 
Macroporous Microspheres [29] and the classical Cultisphere G [30] and Cultiphere S [31], 
while a few examples of resorbable MCs, produced using various techniques and starting 
materials, including their properties and optimal cultivation conditions, can be found in 
the scientific literature [7,8,32–35] (see also Table S1 in the Supplementary Material). 
Hence, we realized that studies combining human stem cells from adipose tissue, biode-
gradable MCs, a defined xeno- and serum-free medium, and dynamic cell culture condi-
tions are scarce. This study aimed to verify whether the biodegradable MC BR44, together 
with the defined xeno- and serum-free medium UrSuppe, are appropriate AMs to cultivate 
adult stem cells. The ASC52telo cell line was used for this feasibility study to expedite and 
facilitate experimentation. This cell line was generated using hTERT-immortalized cells 
extracted from human subcutaneous fat and shown to carefully reproduce most of the 
typical characteristics of primary hASC [36], presenting an ideal cell line for platform val-
idation. In addition to the characterization and comparison of cell growth behavior, spe-
cial emphasis was also placed on critical cell quality attributes (CQAs). We, therefore, be-
lieve that this study can contribute to the development of new protocols for the large-scale 
manufacture of hASCs and lead to a bioreactor-based manufacturing system for the prep-
aration of cell-based therapeutics. 
2. Materials and Methods 
2.1. Production of Microcarrier Prototypes 
MCs were manufactured through the water in oil in water (W1/O/W2) double emul-
sion solvent evaporation method with a foaming agent, according to a modified version 
of the process defined by Kim et al. [25] to obtain a functionalized MC surface with hy-
drophilic components (e.g., gelatin). MCs surface functionalization is crucial since the cell 
culture will be conducted in a defined xeno- and serum-free medium. The cells cannot 
properly attach to nude MCs (data not shown). Initially, a double emulsion volume of 
310.5 mL was used before scaled-up to a final manufacturing process volume of 2066 mL. 
All the further development efforts to optimize the parameters were conducted using this 
final volume. 
Poly(D,L-lactide-co-glycolide) (PLGA) (lactide:glycolide ratio 50:50), Purasorb PDLG 
5002 (Mw 17 KDa), Purasorb PDLG 5004 (Mw 44 KDa), Purasorb PDLG 5010 (Mw 153 
KDa), Purasorb PLC 7015 and Purasorb PLC 9517 (copolymer of L-lactide and ε-caprolac-
tone) were purchased from Corbion Purac. PLGA with Mw 7 KDa (5050 DLG 1A) was 
purchased from Evonik. Polycaprolactones (PCL) with Mw 14 KDa and Mw 80 KDa were 
purchased from Sigma-Aldrich. Polyvinyl alcohol (PVA, 87%–89% hydrolyzed, Mw 31 
KDa) and methylene chloride were purchased from Merck. The bovine and porcine gela-
tine was a generous gift from Italgelatine (Santa Vittoria d’Alba, Italy), and ammonium 
hydrogen carbonate was purchased from Applichem. 
Several of the manufacturing process parameters that affect different MC character-
istics were analyzed. The parameters that were evaluated and mainly affected MCs mor-
phology are as follows: (I) starting polymer raw material, (II) gas foaming agent 
(NH4HCO3) concentration, (III) PVA concentration, and (IV) polymer concentration in the 
hydrophobic phase (O), and (V) primary emulsion (W1/O) and secondary emulsion 
(W1/O/W2) stirring speeds, which affect the MCs PSD. Furthermore, surface functionali-
zation was attempted using: collagen peptides and gelatin from different sources (fish, 
bovine, and porcine). Of course, changes in morphology might lead to a consequent 
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change in PSD. Different functionalization molecules also lead to morphological and par-
ticle dimension changes, thus creating interconnections between the different characteris-
tics. (I) Several polymers that have biodegradability and resorbability features and are 
FDA approved were evaluated. The three main polymers tested were: PLGA (50:50 lactic 
acid/glycolic acid ratio) with different molecular weights (7 KDa, 17 KDa, 44 KDa, and 153 
KDa), PCL (14 KDa and 80 KDa), and two copolymers of lactic acid and caprolactone with 
different monomer compositions. Specifically, PLC 7015 (30% caprolactone and 70% lactic 
acid) and PLC 9517 (5% caprolactone and 95% lactic acid) were used. In general, PCL and 
both PLC (7015 and 9517) tend to be less prone to porous formation during MC manufac-
turing processes, while PLGA tends to form perfectly porous structures (Figure 1). This 
tendency to form a porous surface is reduced when the polymer’s molecular weight in-
creases, independently from the used material (PLGA or PCL). For identical foaming 
agent concentrations, a higher polymer molecular weight results in a less porous surface 
(data not shown). Based on this understanding, PLGA with a molecular weight of 17 KDa 
was selected. (II) The gas foaming agent utilized was NH4HCO3. This was included in the 
aqueous phase of the primary emulsion and spontaneously produced ammonia and car-
bon dioxide gas bubbles during solvent evaporation. This phenomenon resulted in the 
formation of open pores in the interior region and the MC’s surface. As already shown by 
Kim et al. [25], increasing the gas foaming agent’s concentration increases the pores’ num-
ber and size. Concentrations ranging from 0% to 15% w/w in W1 were tested, ultimately 
leading to the selection of 0.3% w/w, which provided an optimal open porous structure 
and an MC density that resulted in sedimentation within an adequate timeframe. (III) Two 
different PVA concentrations were tested in W2: 0.2% and 1%. An increase in PVA con-
centration leads to a reduction in pores on the MC surface and, consequently, to a more 
spherical bead shape, keeping the PSD comparable (data not shown). The selected PVA 
concentration was 0.2% w/w in W2. (IV) The standard polymer concentration in the hydro-
phobic phase of the primary emulsion, according to our protocol, was 4.3% w/w. An in-
crease in polymer concentration to 8.6% w/w led to a reduction in porosity and maintained 
a more spherical MC shape, suggesting that an adjustment in gas foaming agent concen-
tration will be required to maintain the morphological characteristics of the lower poly-
mer concentration. This approach will be followed whenever the manufacturing process 
needs to be scaled up. (V) The stirring of the primary emulsion was performed by a mag-
netic bar. At low stirring speed, the MCs are small, and they do not present the effects of 
the gas foaming agent. High mixing power rates are required to stabilize the emulsion 
and obtain the desired bead morphology and dimension. In general terms, a stable pri-
mary emulsion results in a more homogeneous MC preparation. In the absence of the gas 
foaming agent, the incorporation of air bubbles in the primary emulsion leads to the for-
mation of open porous MCs in the interior region. The final stirring speed of W1/O was 
1400 rpm. In terms of W2, a higher overhead stirrer speed results in smaller MCs since the 
size of the W1/O droplet is reduced by the introduced energy. Therefore, the selected 
speed was 700 rpm during the secondary emulsion formation phase and 300 rpm during 
the overnight evaporation step. During the manufacturing process, several functionaliza-
tions were evaluated to develop a ready to use a product that does not require post-man-
ufacturing coatings. Different protein sources were evaluated, including gelatin and col-
lagen peptides of different animal origins. The difference between gelatin and collagen 
peptides is mainly the amino acid chains’ length, with the collagen peptides having 
shorter chains. This difference affects their solubility and ability to form a gel at room 
temperature. The presence of these proteins positively affects the stability of the primary 
emulsion. Gelatin was successfully incorporated into the MC matrix and surface. More 
difficulties were encountered with collagen peptides, as demonstrated by Bicinchoninic 
Acid (BCA) testing on the final products (data not shown). The difference in water solu-
bility at different temperatures and the smaller molecular weight might explain the diffi-
culty in incorporating the collagen peptides into the polymeric matrix. Bovine and porcine 
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gelatin provide comparable results in morphology and microcarrier PSD; however, por-
cine gelatin is more acceptable for the medical regulatory authorities since it avoids BSE-
related issues, leading to porcine gelatin being the gelatin of choice. 
 
Figure 1. Scanning electron microscopy (SEM) microphotographs to show the morphology of the 
BR44 microcarrier (MC). SEM examination of this carrier showed a good uniformity of shapes and 
sizes. BR44 is highly porous. Fold magnification: (A): 100×, scale bar 1 mm (B,C): 250×, scale bar 300 
µm (D): 500×, scale bar 200 µm. 
2.2. Cell and Culture Medium 
2.2.1. Culture Medium 
The cells used in the experiments were exclusively cultivated using a proprietary de-
fined xeno- and serum-free cell culture medium (UrSuppe), which was specifically formu-
lated to grow human adipose stem cells (hASCs). UrSuppe was developed by testing the 
growth of hASCs with different basal media, several animal-free supplements, and a se-
lected number of recombinant growth factors. Therefore, it only contains defined mole-
cules, some recombinant human growth factors, and injectable human albumin in the µg 
range. 
2.2.2. Cell Expansion and Subculture 
All of the described experiments were performed with ASC52telo cells (ATCC SCR-
400TM). This human adipose stem cell line was immortalized by ectopic expression of the 
human Telomerase’s catalytic subunit (hTERT) [36]. The cells were seeded at a density of 
5000–10,000 cells/cm2 in a T25 flask (TPP, Techno Plastic Products AG, Trasadingen, Swit-
zerland) and incubated in a standard cell culture incubator (37 °C, 5% CO2, rH > 80%) in 
UrSuppe. The medium was replaced every two days until the cells had reached between 
80%–90% confluency. Cells were detached with TrypLE Select (Life Technologies, Thermo 
Fisher Scientific, Waltham, MA, USA) for 2 min at 37 °C, then washed with PBS supple-
mented with 1% human albumin (CSL Behring AG, Bern, Switzerland) and pelleted by 
centrifugation at 400× g for 5 min. After discarding the supernatant, the cells were resus-
pended in UrSuppe and passaged or used for tests with the MC prototypes. 
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2.3. Characterization and Selection of the Prototype MCs 
2.3.1. Selection of a Well-Performing Biodegradable MC Prototype: Cell Attachment 
Studies 
MCs were tested for their ability to allow the attachment of ASC52telo cells under 
xeno- and serum-free conditions. To have a “gold standard” and positive control to com-
pare our MCs’ performance, we choose ProNectin-F MCs (Pall SoloHill, Port Washington, 
NY). This commercial MC performed very well with our defined and other cell culture 
media [37]. The test used for this screening was as follows: (A) Preparation of the cells: 
The cells were detached from the cell culture vessel with TrypLE Select (after 2 min, incu-
bation at 37 °C), washed with PBS supplemented with 1% human albumin, counted with 
Trypan Blue (Life Technologies, Thermo Fisher Scientific, Waltham, MA, USA) and resus-
pended in a culture medium at a concentration of 70,000 cells in 250 µL; (B) Preparation 
of the positive control MC: ProNectin-F MCs (PNF) were incubated in cell culture medium 
for one hour at 37 °C under agitation; C) Preparation of the test MCs: The different biode-
gradable MC prototypes manufactured by Sferalp were washed in PBS and then incu-
bated in UrSuppe for 60 min at 37 °C under agitation. Immediately before the tests, the 
MCs were resuspended in 250 µL of fresh UrSuppe medium, resulting in a theoretical grow 
surface of 2.5 cm2 for the ProNectin-F MC and 1 cm2 for the BR44 prototypes. All of the 
screening tests were performed on low cell attachment plates (Ultra-Low 24 well Multi-
plate, Corning Inc., Corning, NY, USA). MC suspensions of 250 µL were transferred to 
each well, and the plate was gently mixed to distribute the MCs. Then, 250 µL of the 
ASC52telo cell suspension was added. After gently mixing, the plate was placed in an 
incubator (37 °C, 5% CO2), and the cells were cultured for seven days. Every two to three 
days, 50% of the medium was removed and replaced with fresh, preheated UrSuppe me-
dium. After overnight incubation, it was usually possible to identify the low performing 
MCs since very few or no cells were attached to the carriers. The non-adherent cells tended 
to form multiple cellular aggregates (data not shown). Evaluation of the degree of coloni-
zation of the tested MCs was performed using phase-contrast microscopy, fluorescent mi-
croscopy, and SEM (see below). Of all the combinations of organic and biological poly-
mers, shapes, porosities, and other tested parameters, the best combination that resulted 
in a carrier promoting cell attachment and proliferation comparable with a commercial 
product were BR44. Thus, this MC prototype was used for all project-specific experiments 
2.3.2. Dimension of MCs: Particle Size Distribution (PSD) Analysis 
After manufacturing, the MCs were passed through 100 µm and 250 µm sieves to 
obtain a MC fraction within this Particle Size Distribution (PSD) range. The PSD was 
measured using a Sympatec HELOS Laser equipped with a cuvette dispersing system in 
distilled water at room temperature (magnetic stirring required at 800 rpm). An R5 lens 
was used (size range 4.5 to 875 µm), and the trigger conditions were set as follows: time-
base: 1000 ms, start: Ch.10 ≥ 3, valid: 10% ≤ Ch.10 ≤ 25%, duration: 10 s. 
2.3.3. Gelatin Distribution on MC Surface 
According to the manufacturer’s instructions, the MCs were labeled with a Mix-n-
Stain CF®633 Labelling Kit (Biotium Inc., Freemont, CA, USA). This step covalently bonds 
the CF633 fluorophore to the gelatin. The MCs were subsequently mounted on microscope 
slides using 85% glycerol solution (Hänseler AG, Herisau, Switzerland). Images were ac-
quired using a red laser (633 nm) on a confocal microscope Nikon C2 (Nikon, Minato, 
Tokyo, Japan). 
2.4. Bioengineering Investigations 
2.4.1. Sedimentation Velocity of MCs 
The sedimentation velocities of the best performing MC, BR44 MC prototype, and 
the commercially available ProNectin-F MC were measured by imaged-based analysis. 
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For this purpose, 3 µL of the respective MC suspension was added dropwise to a cylin-
drical flow chamber filled with UrSuppe cell culture medium. The sedimentation process 
for the different MC types was recorded with a high definition camera (1920 × 1080 pixels, 
29 fps), and the individual images were analyzed using Matlab (MathWorks, Natick, MA, 
USA) and ImageJ (open source software) to track the single MC particles and to calculate 
the sedimentation velocity distribution for each MC type. The images were only analyzed 
in the lower part of the flow chamber to measure individual MC particles’ maximum sed-
imentation velocities. 
2.4.2. Determination of Ns1u and Ns1 Suspension Criteria 
The suspension criteria (Ns1, Ns1u) were determined for the BR44 MC prototype and 
the commercially available ProNectin-F MC. The method defined by Kaiser et al. [38] and 
Jossen et al. [39] for determining the suspension criteria in a 125 mL Corning spinner flask 
was used. In brief, the Ns1 (Njs, or just suspended) suspension criterion was defined as the 
impeller speed required to just entirely suspend the MCs in the spinner flask [40]. Ns1u 
described the suspension state at which some of the MCs were still in contact with the 
reactor bottom, but none of them were at rest [41]. The suspension experiments were car-
ried out for MC concentrations that corresponded to theoretical growth surfaces of 180 
cm2 and 360 cm2. While the impeller was in motion, the suspension state was recorded by 
a digital camera, and the recordings were subsequently visually evaluated. Optical acces-
sibility to the spinner flask bottom was improved by a mirror that was placed below the 
flask. 
2.4.3. Stability of BR44 under Stirred Conditions 
The BR44 MC prototype’s stability was investigated under stirred conditions (N = 
Ns1u) for up to 14 days in a Corning spinner flask (100 mL) without cells. For this purpose, 
MCs that corresponded to a theoretical specific growth surface of 360 cm2 were resus-
pended in UrSuppe medium and transferred to the spinner flask, which was incubated in 
a standard cell culture incubator (5% CO2, 80% rH). Daily samples were taken and exam-
ined microscopically (EVOS fl auto 2, Thermo Fisher Scientific) to monitor the stability of 
the BR44 MCs and to detect morphological changes. Based on the microscopic images, the 
BR44 MC prototype’s size distribution was determined on day zero and day 14 using Im-
ageJ analysis software. 
2.5. Cultivation Studies 
2.5.1. Cell Adhesion on the MCs: Nuclei Staining with DAPI 
Nuclei staining is a reliable approach for assessing cell density during the MC-based 
culture of adherent cells. After two and four days of growth, MCs with attached cells were 
treated with a fixing solution (2% formaldehyde, 0.2% glutaraldehyde in PBS, Sigma-Al-
drich Inc., St. Louis, MO, USA) for 30 min on ice, washed two times with PBS, and then 
resuspended in 500 nM DAPI (4′,6-diamidino-2-phenylindole) solution (Sigma-Aldrich 
Inc., St. Louis, MO, USA) for 20 min at room temperature in the dark. After two additional 
washing steps, the MC-cell aggregates were resuspended in 85% Glycerol solution and 
mounted for microscopic analysis on µ-Dish (Ibidi, Gräfelfing, Germany). Images were 
acquired using an inverted fluorescence microscope (UV laser 405 nm) Nikon Eclipse Ti 
(Nikon, Minato, Tokyo, Japan). 
2.5.2. Cell Adhesion on MC Prototypes; SEM Analysis 
After two and four days of growth, MCs with cells were fixed in 3% glutaraldehyde 
solution for 30 min on ice, washed twice, and then resuspended in distilled H20. The sam-
ples were then dried directly on a metal specimen stub at room temperature for 3 h. Once 
completely dry, the samples were coated with gold/palladium particles in a Mini Sputter 
Appl. Sci. 2021, 11, 925 8 of 27 
 
 
Coater at 18 mA for 60 s. SEM analysis was performed with a Hitachi TM3030 microscope 
at 15 KV. 
2.5.3. Nuclei Count and Evaluation of Cell Proliferation 
Cell attachment and proliferation were determined by taking periodic samples. MCs 
covered with cells were transferred into 5 mL tubes (Eppendorf, Hamburg, Germany) and 
quickly spun down. After discarding the supernatant, the MCs were resuspended in Lysis 
and Nuclei Extraction Buffer (LNEB: 2% Triton-X, 0.2 M Citric Acid), which lyses the cells 
without altering the MCs. This suspension was then filtered through a micro-strainer with 
a 40 µm mesh diameter (PluriSelect Life Science UG, Leipzig, Germany) to separate the 
nuclei from the MCs. After another centrifugation step at 800× g for 5 min, the cell nuclei 
were resuspended in 100 µL of LNEB buffer and stained with 1.25 ng/µL of 7-AAD. Cell 
nuclei were acquired using a Cytoflex flow cytometer (Beckman Coulter Inc., Pasadena, 
CA, USA), and the data were an alyzed with Kaluza software (Beckman Coulter Inc., Pas-
adena, CA, USA). 
Cell nuclei were gated based on Forward Scatter, Side Scatter, and 7-AAD fluores-
cence. The linear scale of 7-AAD fluorescence was used to discriminate between cells in 
G1-S-G2 phases. For more details, see Supplementary Material (Evaluation of cell prolif-
eration, Figure S1). 
2.5.4. Cellular Detachment 
The cell-MC aggregates were transferred to a 5 mL tube and incubated for 10 min at 
37 °C with TrypLE Select (Life Technologies ThermoFisher Scientific, Waltham, MA, USA) 
under agitation; after dissociation, the hASCs were washed with PBS supplemented with 
human albumin and filtered through a 40 µm microtube mesh to separate the cells from 
the MCs. Both the filter and the wells were washed several times to maximize cellular 
recovery. The cell suspension was pelleted by centrifuging at 400× g for 5 min and then 
resuspended in fluorescence activated cell sorting (FACS) buffer (PBS supplemented with 
1% albumin and 50 ng/µL human immunoglobulins, Privigen Immunoglobulin, CSL Beh-
ring AG, Bern, Switzerland) for flow cytometry analysis, or in Extraction Buffer (7 M Urea, 
1% SDS, 0.35 M NaCl, Sigma-Aldrich Inc., St. Louis, MO, USA) for RT-qPCR analysis. 
2.5.5. Proof-of-Concept Spinner Cultivation 
The ASC52telo cells were used for the proof-of-concept cultivation using the BR44 pro-
totype and the ProNectin-F MCs in a 125 mL Corning spinner flask. MCs that corresponded 
to a theoretical growth surface of 360 cm2 were used (BR44 = 1.01 g, ProNectin-F = 1.0 g) to 
innoculate each spinner flask. The growth surface per spinner flask was defined based on 
previous investigations by Schirmaier et al. [42]. For each condition, one spinner flask was 
inoculated with the ASC52telo cells and cultivated for nine days at 37 °C, with 5% CO2, and 
80% humidity. Both spinner flasks were inoculated with the same inoculum (P24, PDL35), 
which was prepared using T75 flask cultures (10,000 cells/cm2). In addition to the spinner 
flask cultures, the ASC52telo cells were also expanded in a T75-flask as a static control. Be-
fore inoculation, both MC suspensions were equilibrated for 4 h in a cell culture incubator 
in UrSuppe. Post inoculation, no agitation was performed for 24 h to support cell attachment 
on the MC surface. After the cell attachment phase, the impeller was adjusted according to 
the MC-dependent Ns1u criterion. On days four and eight, partial medium exchanges of 50% 
were performed. For this purpose, the impellers were switched off, and the MCs were al-
lowed to settle. Fifty percent of the spinner flasks’ working volume was replaced with fresh 
preheated UrSuppe medium, and the impellers were restarted. 
2.5.6. Spinner Cultivation: Analyses 
Off-line samples were taken daily to measure the substrate (Glc) and metabolite (Lac, 
Amn) concentrations using a BioProfile 100Plus (Nova Biomedical, Waltham, MA, USA). 
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After the cells had detached from the MC surface (15 min TrypLE Select), the cells were 
counted using a NucleoCounter NC-200 (ChemoMetec, Denmark). Based on the regular 
measurements of cell density and substrate/metabolite concentration, growth-dependent 
parameters Equations (1)–(6) were calculated: 
(I) Specific growth rate μ (Equation (1)) 𝜇 = 𝑙𝑛 𝑋 𝑡 − 𝑙𝑛 𝑋 0Δ𝑡  (1)
where μ is the net specific growth rate. XA(t) and XA(0) are the cell numbers at the end and 
the beginning of the exponential growth phase, respectively, and t is the time. 
(II) Doubling time td (Equation (2)) 𝑡 = 𝑙𝑛 2𝜇  (2)
where td is the doubling time, ln(2) the binary logarithm of 2, and μ the specific growth 
rate. 
(III) Population Doubling Level PDL (Equation (3)) 𝑃𝐷𝐿 = 1𝑙𝑜𝑔 2 ∙ 𝑙𝑜𝑔 𝑋 𝑡𝑋 0  (3)
where PDL is the number of population doublings, and XA(0) and XA(t) are the cell num-
bers at the beginning and the end of the cultivation, respectively. 
(IV) Expansion factor EF (Equation (4)) 𝐸𝐹 = 𝑋 𝑡𝑋 𝑡 = 0  (4)
where EF is the expansion factor, XA(tmax) is the maximum cell number, and XA(t = 0) is the 
inoculated cell number. 
(V) Lactate yield from glucose YLac/Glc (Equation (5)) 𝑌 / = ∆𝐿𝑎𝑐∆𝐺𝑙𝑐  (5)
where YLac/Glc is the lactate yield from glucose, ΔLac is the lactate production over a specific 
time period and ΔGlc is the glucose consumption over the same time period (the expo-
nential growth phase) 
(VI) Specific metabolite flux qmet (Equation (6)) 𝑞 = 𝜇𝑋 𝑡 𝐶 𝑡 − 𝐶 0𝑒 − 1  (6)
where qmet is the net specific metabolite consumption or production rate (for Glc, Lac, Amn), 
μ is the specific cell growth rate, XA(t) is the cell number at the end of the exponential 
growth phase, Cmet(t) and Cmet(0) are the metabolite concentrations at the end and the be-
ginning of the exponential growth phase, respectively, and t is the time. 
2.6. Cell Analytics 
2.6.1. Flow Cytometry Analysis 
Reagents: Each test contained different mixtures of the following antibodies: CD73-
FITC, CD105-PE (BioLegend, San Diego, CA, USA), CD34-PE, CD36-APC, CD90-FITC, 
CD146-PE (Miltenyi Biotec, Bergisch, Germany), CD61-PE (Beckman Coulter Inc., Pasa-
dena, CA, USA), CD15-FITC, and 7-AAD (Becton Dickinson, Franklin Lakes, NJ, USA). 
All of the antibodies were titrated to optimize the signal–to–noise ratio and used at a 50 
ng/test concentration. The same final concentrations of the isotype controls and the spe-
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cific mAbs were used. Staining procedure: 50,000 cells (in 100 µL FACS buffer) were pi-
petted into a well, gently mixed with the appropriate antibody combination, and incu-
bated in the dark for 15 min at room temperature. Finally, the sample was diluted with 
100 µL FACS buffer before the cells were acquired. Instrument Setup and Sample Acqui-
sition: Cells were acquired using a Cytoflex flow cytometer (Beckman Coulter Inc., Pasa-
dena, CA, USA) and analyzed using Kaluza software (Beckman Coulter Inc., Pasadena, 
CA, USA). No statistical and significant tests were performed on marker expression. To 
determine the fluorochromes’ spill-over coefficients, fluorescence compensation was as-
sessed using single stained control particles (VersaComp Antibody Capture Bead Kit, 
Beckman Coulter) or cells. The compensation matrix was determined using the Kaluza 
software’s dedicated function. 7-AAD was used to discriminate between dead and live 
cells. Flow-check fluorospheres (CytoFLEX Daily QC Fluorosphere, Beckman Coulter) 
were run periodically to verify optical alignment and fluidics. Detailed information on the 
antibodies can be found in Supplementary Material Table S2. 
2.6.2. RT-qPCR Analysis 
According to the manufacturer’s instructions, RNAs were extracted from cell pellets 
or MCs covered with cells using the Nucleospin®RNA kit (Macherey-Nagel, Düren, Ger-
many). The kit’s purification procedure also includes an on-column digestion step using 
DNase I. RNA purity and quantity were assessed with the NanoDrop device (Thermo 
Fisher Scientific, Waltham, USA) total RNA integrity was periodically verified by conven-
tional agarose gel electrophoresis. cDNA was obtained from 400 ng RNA using the 
GoScriptTM Reverse Transcription System (Promega, Madison, WI, USA), and the proto-
col can be found in Supplementary Material, Table S3. RT-qPCR of the SOX9, RUNX2, 
PPARG, PREF1, ZFP423, ZFP521, WISP2, and DKK1 genes was performed using the 
SsoAdvancedTMUniversal SYBR®Green Supermix kit (Biorad, Hercules, CA, USA) and 
detected using the CFX Connect system (Biorad, Hercules, CA, USA). RT-qPCR was per-
formed for each gene using 20 ng of cDNA, and ACTB was used as an internal control. 
Each primer pair product was checked for proper amplification by agarose gel electro-
phoresis. Only primers that gave rise to single sharp bands of the expected size were used. 
Primer sequences, temperature, and cycle conditions can be found in Supplementary Ma-
terial Tables S4 and S5. The data were analyzed using the CFX software to calculate the 
relative fold gene expression using the formula 2−ΔΔCt. No statistical and significant tests 
were performed on gene expression. 
2.6.3. Secretome Profiler 
ASC52telo cells were grown in standard cell culture vessels (2D static) or spinner 
flasks (ProNectin-F and BR44 MC). The cell culture system was analyzed to detect secreted 
factors. Each conditioned medium was filtered through a 0.22 µm syringe mesh (Jet Biofil, 
Guangzhou, China) to remove cellular debris, then 1 mL of each supernatant was incu-
bated overnight with a nitrocellulose membrane containing 58 different capture antibod-
ies. The array procedure was carried out according to the instructions provided with the 
Proteome Profiler Human Adipokine Array Kit (R and D Systems, Minneapolis, MN, 
USA). Streptavidin conjugated IRDye 800 CW (Li-Cor Corporate, Lincoln, NE, USA) high-
lighted the secondary biotinylated detection antibodies. The positive signals were de-
tected after scanning the membrane using an Odyssey®CLX Imaging System (Li-Cor Cor-
porate, Lincoln, NE, USA). Data were analyzed using Li-Cor software to calculate signal 
intensity ratios between the adipokines and the control reference spots. 
  




3.1. Characterization and Selection of the Prototype MCs 
3.1.1. Shape and Dimensions of the MCs 
More than 50 different MC prototypes were manufactured with different polymeric 
compositions, different gelatines, and peptides derived from gelatin hydrolyzation were 
tested in combination with different shapes, sizes, and porosities of microbeads. After 
founding the best combination that promotes cell attachment and proliferation, we focus 
on the characterization of the biochemical engineering properties of BR44. It consists of a 
mixture of poly lactic-co-glycolic acid (PLGA) and porcine gelatin. Scanning electron mi-
croscopy (SEM) of the BR44 MC showed good uniformity of shapes and sizes (Figure 1), 
comparable with standard commercial MCs composed of natural bio-polymers (see Sup-
plementary Material Figures S2 and S3). 
Analytical characterization of MCs represents an important tool for the comparison of 
prototypes obtained during the screening phase. Figure 2 shows and Table 1 summarizes 
the biophysical properties of the BR44 MC. The results of the particle size distribution meas-
urements demonstrate the reproducibility of the manufacturing process since the size dis-
tribution of the BR44 MCs varied only slightly between the different batches. 
 
Figure 2. Particle size distribution (PSD) of BR44. The figure shows the cumulative and density distribution of one batch 
of BR44 as a representative example. X10 = 116 µm, X50 = 166 µm, X90 = 220 µm. 
Table 1. Biophysical properties of BR44. Data represent the mean of six different batches of BR44. 
Concentration (g/mL) Particle Size Distribution (PSD) (µm) Theoretical Surface (cm2/g) X10 X50 X90 
0.034 ± 0.0002 116.76 ± 1.93 166.41 ± 3.44 221.55 ± 3.56 355.77 ± 6.04 
3.1.2. Proof of Homogeneous Gelatin Distribution on MC Surfaces 
Gelatin is essential for cell attachment in a serum-free medium. Therefore, it was cru-
cial to establish how the porcine gelatin proteins are distributed on the surface of the MC 
prototype BR44. For this purpose, the CF633 fluorescent dye was used to conjugate the 
proteins to check their presence and distribution (porcine gelatin) on the surface of BR44 
(Figures 3 and 4). The BR13C MC prototype, which does not contain proteins and is made 
of pure PLGA (see Supplementary Material Figure S4), was chosen as a negative control 
for this test. Various commercial MCs either with surfaces (peptides or primary amines) 
that react to the CF633 dye or with a protein coating (Collagen I, Fibronectin, Gelatin) on 
their outer shell were used as a positive control. The analysis of these MCs was also intri-
guing because it demonstrated how some companies solved the problem by coating their 
microspheres’ surface layer to allow adhesion and cell growth. The results obtained with 
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these commercial MCs are shown in Supplementary Material Figure S5. The CF633 fluo-
rescent dye (molecular weight ~820 g/mol) reacts with the accessible primary amines of 
proteins, highlighting their presence and distribution on the MC BR44 prototype’s surface. 
As shown in Figure 3, the porcine gelatin proteins are homogeneously distributed and 
present at a high density on the carrier’s surface. Furthermore, the images demonstrate 
and confirm that this MC is also highly porous on the inside. 
 
Figure 3. Fluorescent microphotographs of the MCs prototypes. (A) BR13 (negative control): 
poly(D,L-lactide-co-glycolide) (PLGA) MCs without gelatin after reaction with the CF633 dye, expo-
sure time: 400 ms, no fluorescence in the red channel. Magnification 100×, scale bar 150 µm. (B) BR44 
no staining with the CF633 dye (negative control), no fluorescence in the red channel. Magnification 
100×, scale bar 150 µm. (C) BR44 reaction with the CF633 dye, exposure time: 400 ms. Magnification 
200×, scale bar 150 µm. 
 
Figure 4. Confocal microscopy analysis of the prototype BR44 MC stained with the fluorescent 
CF633 dye. (A). 2D convolution. (B,C). Microphotographs of two different sections. Magnification 
400×, scale bar 100 µm. 
3.2. Bioengineering Investigations 
3.2.1. Sedimentation Velocity Distribution of BR44 MC 
The sedimentation velocities of the BR44 prototype ranged between 0.13 mm/s and 
2.2 mm/s, whereas the values for the ProNectin-F MC ranged between 0.38 mm/s and 3.57 
mm/s. Thus, the mean sedimentation velocities of the BR44 prototype (0.63 mm/s) were 
up to 56% lower than those measured for the ProNectin-F MC (1.46 mm/s). 
3.2.2. Suspension Studies with the BR44 and ProNectin-F MCs 
Different BR44 MC suspension states are represented in Figure 5 for the Corning 
spinner flask. As can be seen from the images, different suspension states can be detected: 
(I) transport of the MCs to the vessel center and the formation of a clear outer zone, (II) 
swirling up of the MCs from the center of the vessel bottom and further reduction of the 
MC solid fraction at the reactor bottom, and (III) maintaining the BR44 MCs in suspension 
(Ns1u < N < Ns1). Comparable suspension states were also observed for the ProNectin F MC. 
Table 2. shows the results of the suspension studies using the BR44 prototype and the 
ProNectin-F MC. The impeller speeds determined for Ns1u were between 75 and 85 rpm 
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for the BR44 MC and between 35 and 49 rpm for the ProNectin-F MC. Thus, up to 2.1-fold 
higher impeller speeds were required to suspend theoretical growth surfaces of 180 cm2 
and 360 cm2 for the BR44 MC. Comparable observations were also found for the Ns1 crite-
rion, which was between 90 and 102 rpm for the BR44 MC and between 44 and 60 rpm for 
the ProNectin-F MC (see Supplementary Material “Calculation of important biochemical 
engineering parameters”). The resulting Reynolds numbers for the determined impeller 
speeds indicated that an MC suspension was achieved in a Corning spinner flask under 
transient fluid flow conditions. This finding was in good agreement with observations 
from Kaiser et al. [38] and Leber et al. [43] for different kinds of MCs. Based on the values 
determined for Ns1u and Ns1, the specific power input (P/V) and the local volume-weighted 
mean shear stress (τnt) values were derived according to the method outlined by Jossen et 
al. [39]. Taking the P/V and τnt into account, up to 4.4 and 2.2-times higher values were 
required to suspend the BR44 MC than for the ProNectin-F MC, which can be explained 
by the different chemical nature of the two polymers. 
 
Figure 5. BR44 MC suspension dynamics. Photographic pictures (side and bottom view) of the MC 
distribution during the suspension studies. Ns1 was defined as the impeller speed required just en-
tirely to suspend all MCs. Ns1u was defined as the lower limit of Ns1, meaning that some MCs were 
still located at the bottom of the flask, but none were at rest. 
Table 2. Overview of Ns1u/Ns1 and dependent biochemical engineering parameters. (*) P/V values and (**) local volume-
weighted mean shear stress levels were derived from Jossen et al. [39]. utip indicates the maximum expected fluid velocities 
in a stirred bioreactor. Re is used to classify the fluid flow regime in a stirred bioreactor. P/V represents an important 
parameter in terms of process scale-up and the estimation of hydrodynamic stresses. τnt gives an overview of the hydro-
dynamic stress acting on the cells in a stirred bioreactor system. 
 Theoretical AMC (cm2) Ns1u/Ns1 (rpm) utip (m/s) Re (-) P/V * (W/m3) τnt ** (10−3 Pa) 
BR44 
180 75/90 0.16/0.19 2095/2514 1.42/2.31 8.3/10.0 
360 85/102 0.18/0.22 2374/2849 1.96/3.39 9.4/11.3 
ProNectin-F 180 35/44 0.08/0.09 978/1229 0.35/0.52 3.8/4.8 
360 49/60 0.11/0.13 1369/1676 0.62/0.88 5.4/6.6 
3.2.3. BR44 Stability under Stirred Conditions 
Figure 6(A1,A2) shows light microscopic pictures of the BR44 MC during the stability 
tests in the Corning spinner flasks. During the 14-day incubation period at Ns1u (85 rpm), 
no significant increase in debris or broken BR44 MCs was observed, indicating that the 
BR44 MC was stable under culture-relevant conditions. However, the size distribution 
analysis after 14-days showed a decrease in the MC size distribution (Figure 6B) MCs’ 
mean diameter decreased by up to 37%, suggesting the MCs shriveled during the 14-day 
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incubation period under stirred conditions. However, the MCs’ shrinkage can be ex-
plained by the biodegradable property of PLGA and was, therefore, to be expected (see 
also Figure S6). 
 
Figure 6. BR44 stability and size distribution. (A1,A2) Phase-contrast light microscopic pictures of the BR44 MC during 
the stability test in the Corning spinner flask (N = Ns1u) at day zero and 14. (B) Size distribution after equilibration (4 h) of 
the BR44 MC in UrSuppe (day 0) and after 14 days incubation under stirred conditions. 
3.3. Cultivation Studies 
3.3.1. Attachment and Growth of the ASC52telo on BR44 MCs under Static Conditions 
In static culture tests, the BR44 prototype obtained good results without using particu-
lar protocols. Therefore, we performed a titration to defined the optimal cell density to use 
with the BR44 MCs. Examples of cell attachment and growth on the BR44 MCs are shown 
in Figures 7 and 8 and Supplementary Material Figure S7 The BR44 MCs were entirely col-
onized by the ASC52telo cells, and the formation of large aggregates was observed after a 
few days of culture in static conditions with the UrSuppe medium. Therefore, the BR44 MC 
is a three-dimensional (3D) scaffold suitable for growing human cells in xeno- and serum-
free conditions. Since it is often challenging to quantitatively detach cells from the MCs on 
which they have grown, a protocol based on nuclei counts was developed. A cell lysis buffer 
solution extracts the nuclei that can subsequently be enumerated by flow cytometry, allow-
ing their cell cycle status to be assessed. Therefore, it is possible to calculate the percentages 
of actively proliferated cells attached to BR44 (see Table 3, and for more details, see Supple-
mentary Material Figures S8 and S9). ASC52telo cells proliferated well on BR44, with a 5/6-
fold increase in cell numbers and an excellent active proliferation rate (over 50% on the last 
day of measurement) being measured over eight days of cultivation. Growth curve reported 
in Supplementary Material Figure S10. It was concluded that ASC52telo cells readily adhere 
to the BR44 MC prototype’s surface and that a significant percentage of them continued to 
proliferate during the sampling days actively. 




Figure 7. SEM microphotographs to confirm the presence of ASC52Telo cells on MC BR44 surface 
after four days of culture in static conditions. Fold magnification: (A): 50×, scale bar 2 mm (B,C): 
250×, scale bar 300 µm (D): 500×, scale bar 200 µm. Interestingly, the cells are tiny and packed to-
gether, which is a feature often found with undifferentiated/immature cells. 
 
Figure 8. Confocal laser-scanning microscopy analysis of BR44 MCs after two days of culture. (A) 
The strong natural autofluorescence of the cells can be exploited to visualize the hASCs grown on 
the surface of the BR44 carrier. (B) The DAPI staining reveals the presence of several nuclei on the 
surface of BR44. (C) Merged. Magnification 400×, scale bar 100 µm. 
Table 3. Analysis of the nuclei by flow cytometry. The nuclei can be divided into three groups 
based on different DNA amount. The three phases of interest, G1, G2, and S, are distinguishable 
(see Supplementary Material Figures S8 and S9). The data are shown for the four measurements 
(day 1, 3, 6, and 8). The table shows the number and percentages of nuclei found in G1, G2, or S 
phase for ASC52telo grown on BR44. The active proliferation percentage (APP) was calculated as 
follows: APP = ((G2 + S)/G1) × 100. 
 Nuclei % G1 % S % G2 APP 
Day 1 40’760 71.89 7.96 10.65 25.89 
Day 2 55’520 56.54 17.99 15.47 59.18 
Day 6 230’960 67.32 12.54 11.82 36.19 
Day 8 222’948 55.97 14.15 15.48 59.94 
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3.3.2. Proof-of-Concept: Spinner Cultivation with BR44 and ProNectin-F MCs 
Table 4 summarizes the results of the proof-of-concept cultivation. The data shows 
that the ASC52telo cells proliferated on the BR44 MC under dynamic conditions (growth 
curves can be found in Supplementary Material Figure S11). A maximum specific growth 
rate of up to 0.35 d−1 was obtained, which corresponded to a doubling time of 2.0 d. Thus, 
a maximum cell density of 1.2 × 105 cells/mL (EF 7.0) was achieved at the end of the culti-
vation. Cell growth on the ProNectin-F MC was 1.6-times faster (μmax = 0.56 d−1 and td = 
1.24 d). Thus, the maximum cell density (7.5 × 105 cells/mL) and the expansion factor (21.3) 
were 7.5 and 3.1-times higher, respectively, after nine days of cultivation. This might re-
sult from the lower cell attachment efficiency of the BR44 MC compared to the ProNectin-
F MC. In both cases, the ASC52telo cells consumed glucose (qGlc,BR44: 21.7 pmol/cell/d, 
qGlc,PNF: 7.78 pmol/cell/d) and produced lactate (qLac,BR44: 137.8 pmol/cell/d, qLac,PNF: 41.2 
pmol/cell/d) and ammonia (qAmn,BR44: 7.3 pmol/cell/d, qAmn,PNF: 1.6 pmol/cell/d). In both cul-
tivations, no critical substrate or metabolite concentrations were achieved (LacPNF = 26.87 
mmol/L; LacBR44 = 21.31 mmol/L, AmnPFN = 0.96 mmol/L, AmnBR44 = 0.65 mmol/L); however, 
cells growing on BR44 MC could experience a high localized concentration of lactate, 
which would constantly be released from the MC core. This is suggested by the calculated 
amount of lactate (in pmol) released per cell and per day, which is three times higher for 
the BR44 MC (~138 pmol/cell/day) than for ProNectin-F MC (~41 pmol/cell/day). This high 
concentration of localized lactate may have been the reason for the slower growth rate 
and doubling time observed for the tests performed with BR44 MC, as lactate is known to 
inhibit cell growth [44]. Furthermore, we noticed that cultures based on the BR44 MC eas-
ily generate clusters, even under dynamic conditions. This phenomenon is much less rel-
evant when ProNectin-F MC was used. Cell-MC clusters could lead to a decrease in cell 
density due to nutrient diffusion limitations to aggregate centers. The calculated average 
Ylactate/glucose values are superior to the theoretical values of 2 for both MCs type (YLac/Glc, BR44 = 
6.35; YLac/Glc, PNF = 5.29). This suggests that alternative substrates such as glutamine, serine, 
and possibly other amino acids are used for energy generation and contribute to the meas-
ured lactate concentration [45]. During these catabolic reactions, ammonia is produced, 
which we detected in significant quantities, especially in the presence of MC BR44 (~4.5 
times higher than with MC ProNectin-F), supporting the previous suggestion. It is well 
known that glutamine is chemically labile in the cell culture medium, and thus ammonia 
could arise through spontaneous hydrolyzation of this amino acid [46,47]. However, the 
amounts detected could not be explained with only the spontaneous degradation of glu-
tamine in cell culture conditions. As low levels of ammonia in the cell culture medium are 
known to inhibit cell growth [31], the cells grown on MC BR44 would be at a further dis-
advantage compared to those grown on ProNectin-F, where ammonia concentration per 
cell and per day was approximately 4.5 times lower. Taken together, the findings suggest 
that the type of MC used has an influence on the type of metabolism adopted by the cells 
during cultivation. 
Table 4. Overview of main growth-dependent parameters. 
Parameter BR44 ProNectin-F 
μ (d−1) 0.35 0.56 
td (d) 2.01 1.24 
Atteff (%) 38.7 78.2 
Xmax (105 cells/mL) 1.2 7.5 
EF (-) 7.0 21.3 
YLac/Glc (mmol/mmol) 6.35 5.29 
qGlc (pmol/cell/d) 21.74 ± 9.12 7.78 ± 1.83 
qLac (pmol/cell/d) 137.88 ± 40.64 41.24 ± 19.39 
qAmn (pmol/cell/d) 7.32 ± 3.71 1.61 ± 0.74 
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μ: Specific cell growth rate. td: Doubling time of cell population. Atteff: Attachment efficiency. Xmax: 
Maximum cell concentration on planar growth surface. EF: Expansion factor. YLac/Glc: Lactate yield 
per glucose equivalent. qGlc: Specific glucose consumption rate. qLac: Specific lactate production 
rate (growth-dependent). qAmn: Specific ammonium production rate (growth-dependent). 
3.4. Cell Analytics 
3.4.1. Flow Cytometry Analysis of ASC52telo Cells Cultured in Static 2D or Dynamic 3D 
Conditions 
It was desirable to verify whether the ASC52telo cells growing on BR44 (3D condi-
tions) express the same standard surface markers and maintain the same stemness level 
as a batch of the same cells cultivated in traditional cell culture vessels (2D conditions). 
Flow cytometry analysis of some common surface antigens suggested no significant dif-
ferences between cells grown in 2D and those grown in 3D on BR44. Essential markers for 
stemness are preserved (CD73, CD90, and CD105), and adipogenic markers (CD34, CD36, 
and CD146) upregulated during adipogenic differentiation are not expressed in 3D con-
ditions (see Figure 9 and Supplementary Material Figures S12 and S13) [48]. CD61 is a 
control marker that is usually not expressed by human fibroblasts [49]. 
 
Figure 9. Flow cytometry data were summarized and depicted using a “Radar Plot” for ASC52telo 
cells cultured in xeno- and serum-free conditions (UrSuppe). The diagram shows the percentage of 
positive cells for the respectively indicated surface marker. Cells were cultured either in 2D (T25 
flask) or on the BR44 (3D condition). 
3.4.2. Expression Levels of Some Essential Genes Involved in Cell Stemness or Cell Dif-
ferentiation Measured by RT-qPCR 
Several genes have been discovered to seal the undifferentiated status of hASCs and 
other genes required for their differentiation (Figure 10A). Further information about a se-
lection of these genes, including a short description and references, can be found in Supple-
mentary Material Tables S6 and S7. Some of them are useful as markers in RT-qPCR assays 
to check the in vitro expanded cells’ differentiation status. In these experiments, ASC52telo 
cells were grown in standard cell culture vessels (2D static) or spinner flasks on BR44 (3D 
dynamic). RT-qPCR measured the expression levels of some of the selected marker genes, 
and the values were compared to those obtained in static 2D conditions. PREF1, WISP2, 
ZFP521, and SOX9 are among the essential genes linked with the undifferentiated status 
and against differentiation of adipose tissue progenitor cells. Interestingly, an increase in the 
expression of these markers was observed in 3D cultures. PPARG, ZFP423, DKK1, and 
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RUNX2, are related to the commitment to an adipogenic (chondrogenic for RUNX2) lineage 
and differentiation. In 3D cultivations, a down-regulation of two of these important genes 
(PPARG and DKK1) was observed (see Figure 10B), meaning better preservation of the un-
differentiated status of the cells compared to the 2D static situation. 
 
Figure 10. Expression ratio measured by RT-qPCR of some essential genes which regulate positively 
or negatively the adipocyte differentiation process. (A) The illustration schematically shows the re-
lationship between different factors that positively or negatively controls adipogenesis. Two of them 
are particularly important: PPREF1 is known to inhibit adipogenesis and, PPARG, considered the 
master regulator of adipose tissue development and differentiation. The blue dotted line represents 
the various differentiation stages that lead to a mature adipocyte starting from a progenitor cell. 
Further information and references about the marker genes used can be found in Supplementary 
Material, Tables S6 and S7. (B). Representative experiment showing differences in marker genes 
expression between ASC52telo cells grown in static 2D or defined dynamic 3D conditions. The nor-
malized expression ratio of the different markers for the defined dynamic 3D tests is related to the 
static 2D condition values. 
3.4.3. Comparing the Secretome Profile of ASC52telo Cells Grown in Standard Static 2D 
vs. Dynamic 3D Conditions 
Since some polypeptides are only produced and secreted during certain precise 
stages of development or maturation, they can be used to diagnose a specific metabolic 
state or a specific differentiation degree of the cells under investigation. To assess the pres-
ence of 58 human adipokines, we used a commercially available “Proteome Profiler Hu-
man Adipokine Array” (see Table 5, Figure 11, and Supplementary Material Figure S14 
and Table S8). Interpreting and finding a biological sense for a proteome profiler array is 
always very difficult, especially if many polypeptides are detected. In this case, which 
fortunately is not too complex, we notice some trends that allow us to interpret the ob-
tained results. First, the detected polypeptides were already associated by other reports 
with the adipose tissue secretome (for a review, see [50]). Second, to facilitate the data’s 
comprehension, it is possible to group the secreted polypeptides according to some char-
acteristic traits that unite them. Two signature adipokines (adiponectin and leptin) for 
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differentiated cells were undetectable in the test membranes, and the spot corresponding 
to Nidogen/Entactin was very weak. These results prove that most ASC52telo cells remain 
undifferentiated and immature. We detected three Cathepsin family members. These pro-
teins are proteases that play different crucial roles in mammalian cellular turnover. Ca-
thepsin S promoted human preadipocyte differentiation [51] and was found only in the 
culture medium of cells grown under 2D conditions. A critical role of the Insulin-like 
growth factor-binding proteins (IGFBPs) is to regulate Insulin-like growth factors (IGF-I 
and IGF-II) action by controlling the accessibility of these peptide hormones to their re-
ceptors [52]. Both IGF-I [53] and IGF-II [54,55] are pro-adipogenic. It has been shown that 
IGFBP-4 binds IGF-I and its expression negatively correlates with adipose tissue growth 
[56]. IGFBP-6 is not well characterized but is likely to be anti-adipogenic, too, as it can 
bind IGF-II [57]. Pregnancy-associated plasma protein-A (PAPP-A) is a zinc metallopro-
teinase regulating local insulin-like growth factor (IGF) action through cleavage of inhib-
itory IGFBPs, in particular IGFBP-4. This is the primary mechanism by which PAPP-A 
enhances local IGF bioavailability for receptor activation. PAPP-A is expressed primarily 
by pre-adipocytes in fat tissue [58]. So, IGFBP-4, IGFBP-6, and PAPP-A belong to a circuit 
that regulates IGFs’ availability, which in turn positively regulates adipogenesis. IGFBP-
4 and IGFBP-6 were detected in the supernatants of cells cultured in 2D and 3D/PNF MC 
conditions, but not when the BR44 MC was used, whereas PAPP-A only in 2D condition. 
The proteome profiler array also highlighted the presence of some cytokines [59] and 
chemokines [60] in the cell-conditioned culture media: IL-6, CXCL/IL-8, CCL2/MCP-1, 
MIF, and CCL5/RANTES. Interestingly, IL-6, CCL2/MCP-1, and CCL5/RANTES were de-
tected only in cells grown in 2D conditions. On the other hand, IL-8 and MIF were detected 
in 2D and 3D (see Table 5 and Figure 11). Pentraxin 3 (PTX3), also known as tumor necro-
sis factor (TNF)-inducible gene 14 protein (TSG-14), is a pattern recognition molecule that 
functions in innate immunity and is a useful biomarker of a pro-inflammatory status [61]. 
Remarkably, this polypeptide was detected only in the supernatants of cells cultured in 
2D and 3D/PNF MC conditions, but not when the BR44 MC was used. These observations 
suggest that the defined dynamic 3D conditions might lead the cells to secrete fewer in-
flammatory factors, and BR44 MC seems more suitable than PNF MC to induce this phe-
nomenon. As a last interesting factor found only in the supernatant of cells grown in 2D 
or 3D combined with BR44 MC, there is Serpin E1/PAI-1. Plasminogen activator inhibitor-
1 (PAI-1), a serine protease inhibitor family member, inhibits fibrinolysis and has complex 
cellular matrix interactions. PAI-1 deficiency or inhibition stimulates adipocyte differen-
tiation. Therefore it can be considered an anti-adipogenic factor [62]. In summary, these 
results suggest that the secretion profile of ASC52telo depends on the cultivation system 
(standard static 2D vs. dynamic 3D). Interestingly, when these cells grew on BR44 in a 
dynamic system, the secretion profile is less complex. This may suggest that the cells re-
main more immature, thus preserving better “stemness”. This observation is in good 
agreement with the results obtained by RT-qPCR. Ultimately, culturing ASC52telo cells 
on MCs in a dynamic 3D cell culture system using the UrSuppe medium seems to enhance 
the cells’ undifferentiated status and reduces the secretion of pro-inflammatory media-
tors. 
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Table 5. Summary of the relevant secreted factors of ASC52telo cells cultured in standard cell cul-
ture vessels (2D) or dynamic conditions (spinner flask, 3D). In this latter case, the cells were cul-
tured either on BR44 MC or commercial ProNectin-F (PNF) MC. Interestingly, the secretion profile 
of cells grown in 3D is less complex than the one obtained in the 2D condition. Moreover, when 
the BR44 MC is used, the number of secreted polypeptides detected is further reduced compared 
to PNF MC. These results suggest that the secretome of ASC52telo cells can be influenced by the 
cell culture conditions (2D vs. 3D) and the microcarrier type on which they grow (BR44 vs. PNF). 
A less complex profile of secreted adipokines in 3D conditions may also signify that the ASC52telo 
better preserve their undifferentiated status when they grow on MCs in a defined dynamic sys-
tem. The UrSuppe medium was used in all conditions tested for these investigations. For more 
details about these experiments, see Supplementary Material Figure S14. 
Analyte/Control 2D  ASCs 52telo 
3D  
ASCs 52telo BR44 
3D  
ASCs 52telo ProNectin-F 
Cathepsin D X X X 
Cathepsin L X X X 
Cathepsin S X   
IGFBP-4 X  X 
IGFBP-6 X  X 
Pappalysin-1/PAPP-A X   
IL-6 X   
CXCL8/IL-8 X X X 
CCL2/MCP-1 X  X 
MIF X X X 
CCL5/RANTES X   
Pentraxin-3/TSG-14 X  X 
Serpin E1/PAI-1 X X  
TIMP-1 X X X 
Endocan X   
HGF X  X 
ICAM-I/CD54 X   
Nidogen-1/Entactin X  X 
 
Figure 11. Comparison of the secretome profiles of ASC52telo cells cultured in standard cell culture 
vessels (2D) or dynamic conditions (spinner flask, 3D). In this latter case, the cells were cultured 
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either on BR44 MC or commercial ProNectin-F MC. The calculated levels are expressed as a per-
centage relative to the reference spot present on the membrane. Remarkably, the secretion profile 
depends on the three culture conditions (2D, 3D spinner ProNectin-F, and 3D spinner BR44) tested 
in this study. 
4. Discussion 
PLGA is the most widely used synthetic biodegradable material due to its excellent 
biocompatibility, non-toxicity, and non-immunogenicity [63]. Indeed, PLGA is generally 
recognized as safe for use in particular pharmaceutical products such as degradable su-
tures, stents, screws, bone plates, and wound dressing by international regulatory agen-
cies, such as the United States Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA). PLGA is considered the “material of choice” to manufacture 
biodegradable MCs or scaffolds since its degradation products are quickly metabolized in 
the body via the Krebs cycle [44,45]. PLGA has also been used as a core polymer to man-
ufacture MCs to culture anchorage-dependent cells, which require large surface areas for 
attachment and growth. However, pure PLGA carriers do not inherently possess cell-ad-
hesion motifs. Different approaches have been proposed to functionalize the MC surface 
and allow efficient attachment and proliferation of anchorage-dependent cells [21]. There-
fore, it was decided to synthesize gelatin-PLGA composite MCs by emulsifying gelatin in 
a PLGA/dichloromethane solution, followed by a modified water-in-oil-in-water double 
emulsion solvent evaporation method [25]. Gelatin is a naturally derived polymer, has a 
chemical structure similar to collagen, thus mimicking the natural extracellular environ-
ment [64]. However, it is a product of animal origin and, therefore, potentially able to 
initiate an immunological response or transmit zoonotic diseases is a drawback. Never-
theless, gelatin has a long history of clinical use, with few adverse outcomes [65,66]. More-
over, bovine gelatin was replaced by porcine gelatin to avoid Bovine Spongiform Enceph-
alopathy (BSE) related issues. For the orthopedic application of stem cells, it is realistic to 
plan for ex-vivo cultivation, a manufacturing period of approximately two months. Three 
to four weeks are needed to amplify the stem cells and as many weeks again to differen-
tiate them into chondrocytes or osteocytes. It is known that during differentiation, the 
extracellular matrix (ECM) is replaced with one more suited to their new role as mature 
cells [67]. We estimate that porcine gelatin makes up approximately 10% of the MC. Thus, 
it is very likely that there will be very little residual porcine gelatin remaining at the time 
of implantation of the engineered tissue, reducing the risk of an immunological reaction. 
Nevertheless, further steps are planned to replace porcine gelatin with recombinant hu-
man ECM proteins or biomimetic peptides [68]. This is also a necessary step toward re-
specting the ethical or religious convictions of a considerable number of human beings 
who do not allow the consumption or use of products of porcine or bovine origin. 
Several types of MCs were manufactured and examined. Still, only a specific combi-
nation of organic and biological polymers, shape, and porosity, among other tested pa-
rameters, resulted in a MC prototype with the desired functionality and promoting cell 
attachment and proliferation. The BR44 MCs allow ASC52telo cells to attach to their sur-
face, grow in a defined serum-free cell culture medium in a static or a dynamic system, 
and maintain or even enhance their undifferentiated status. The biochemical engineering 
parameters were also very close to those found for commercial non-biodegradable MCs 
(e.g., ProNectin-F). We also experimentally determined the biophysical characteristics of 
BR44 MC and analyzed the morphology and distribution of gelatin on the microspheres. 
We found that BR44 MC is very porous, and the gelatin is homogeneously blended with 
the synthetic polymer. The chemical structure of PLGA is illustrated in Figure 12A, and a 
cartoon in Figure 12B tries to reproduce, in a very schematic and naive way, how the bio-
compatible scaffold shaping BR44 MC might look like at the molecular level. PLGA forms 
a compact and dense nano-fibrous structure on which gelatin deposits and attaches non-
covalently to the synthetic polymer. 




Figure 12. Chemical structure of PLGA (A) and cartoon (B) suggesting how the PLGA/gelatin mix might resemble. (A) 
Structure of PLGA. (B) Tight and dense nano-fibrous structure of embedded gelatin on PLGA fibers. The interaction be-
tween the two polymers is non-covalent. The uniform distribution of the gelatin allows the formation of a biodegradable 
MC with cell adhesion suitable surfaces. 
During these studies, we had the opportunity to understand the drawbacks of bio-
degradable PLGA based MCs. First, lactic acid is continuously released from this MC type 
during the cell culture procedure and adds to that secreted by cells. Indeed, as shown in 
Table 4, we measured about three times more lactic acid when the ASC52telo were grown 
on BR44 (qLac: ~138 pmol/cell/d) compared to the value found when ProNectin-F MCs 
(coated polystyrene microsphere, qLac: ~41 pmol/cell/d) were used for the experiments. 
Lactic acid can inhibit cell growth [44]: ASC52telo growing on BR44 could experience a 
much higher local lactic acid concentration than the cells cultured on ProNectin-F MCs. 
Therefore, this could explain the lower growth rate and the higher doubling time of a 
BR44 MC-based culture compared to one dependent on ProNectin-F MCs. The type of MC 
used to culture the ASC52telo cells influences their metabolism. Indeed, with BR44, there 
is also a higher ammonia production per cell and per day. It is known that a low level of 
ammonia in the cell culture medium inhibits cell growth. This, together with the lactic 
acid production, could explain the lower cell yield obtained with MC BR44. Second, the 
BR44 MC is more challenging to handle than the synthetic ProNectin-F counterpart since 
it easily sticks to pipettes and other equipment commonly used in the laboratory to 
transport or measure a powder or a liquid. However, we noticed that this characteristic is 
also shared by other MCs manufactured with organic or biological polymers, such as 
Cultispere S and G, Cytodex 3, and Celnest’ Macroporous MCs (Fujifilm). This problem 
can be alleviated by using “low retention” (Repel Polymer Technology, RPT) tips and pi-
pettes. Third, this innate propensity, typical for MCs with a biopolymer core to stick to-
gether, is also maintained in culture with cells. Thus, even under dynamic conditions, this 
can lead to the formation of large aggregates. Therefore, it is necessary to optimize the 
stirring conditions to reduce this phenomenon, which may lead to a decrease in cell den-
sity due to the limitation in the diffusion of nutrients to the center of large cell-MC clusters. 
Therefore, MCs with a biopolymer core require a more laborious setup concerning the 
seeding densities and the agitation parameters compared to classic MCs with a synthetic 
core. Fourth, despite the sedimentation velocity of the BR44 being excellent (≈0.63 mm/s) 
and comparable to the commercial MC ProNectin-F (≈1.46 mm/s), the impeller speed nec-
essary to keep the BR44 in suspension was up to 2.1-fold higher than the one used for the 
MC ProNectin-F. Jossen et al. [39,69] have recently shown that cells start to experience 
increased hydrodynamic stress above a specific impeller speed, which leads to a signifi-
cant decrease in the specific growth rate. Thus, together with the higher concentration of 
lactate and ammonia, this observation can explain the decreased cell yield when the BR44 
is used to culture ASC52telo cells. A possible explanation for this observation is that BR44 
is very porous and has an irregular shape. This could increase the hydrodynamic drag 
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and require a higher impeller speed to keep the carriers in suspension. Finally, while syn-
thetic MCs, such as ProNectin-F, have perfectly spherical, smooth, and are all approxi-
mately the same size, those made with organic or biological polymers often have an irreg-
ular shape, inhomogeneous dimensions, and can be very porous (see Figures S2 and S3). 
This makes it difficult to determine with certainty the total surface available for growing 
cells. Consequently, finding the optimal seeding density in these cases is more based on 
empirical tests than on precise calculations. 
Growth kinetics of ASC52telo on BR44 is similar to other MCs culture, consisting of 
slow initial growth, followed by an exponential growth phase until cells reach a stationary 
level after, determined by the surface/nutrient availability, after a week [70]. In our previ-
ous paper, we study primary human ASCs growth parameters in UrSuppe on commercial 
MC. We observed that the number of cells fluctuated around a specific maximum value 
determined by the system [37]. One of the most important preliminary results obtained 
after these experiments is that the undifferentiated state of the ASC52telo cells is very well 
preserved when growing on biodegradable MC. This is independent of the cell culture 
system since this was observed both in static and dynamic (stirred flask) conditions. In 
static or dynamic conditions, we found that cells grown in 3D on BR44 showed a better 
“gene expression profile for stemness” than the same cells cultured on traditional 2D sur-
faces (as shown in Figure 10B). We also observed that the secretion profile of ASC52telo 
cells depends on the cultivation system (standard static 2D vs. dynamic 3D) and the MC 
type on which the cells grow (BR44 vs. ProNectin-F, see Table 5, Figure 11, and Figure 
S14). These observation are in accordance to previous papers that indicates that 3D envi-
ronment mimic the in vivo conditions and are able to better preserve stemmnes [71]. In-
terestingly, when these cells expand on MCs in a dynamic system, the adipokines profile 
is less complex. This could mean that the cells remain more immature, thus better pre-
serving their stemness. This observation agrees with the results obtained by RT-qPCR. We 
also noted that the type of MC used to grow the cells also influences the type of metabo-
lism adopted during the culture period. So, we concluded that although the system based 
on an agitated bioreactor, microcarrier, and a defined serum-free medium may seem very 
artificial, the cells like it and maintain the same or a superior undifferentiated status com-
pared to cells grown in standard 2D conditions. We thought of explaining this phenome-
non with the following hypothesis. Except for blood and endothelial cells, all the other 
cells are normally never in contact with serum. They are in contact with the interstitial 
fluid, which has a lower concentration of proteins than serum and is specific for each tis-
sue or organ due to a unique composition of secreted polypeptides and metabolic mole-
cules [12,13]. Paradoxically, it is similar in composition to a serum-free medium, which is 
generally not as complex as serum and is specific to the cell type of interest. Furthermore, 
cells are organized in 3D structures, and they experience movements and hydrodynamic 
and shear stresses: Fluids flow through, contractions, movements, and motor activity are 
widespread actions in the animal kingdom. Thus, it may be possible that the conditions 
created in an agitated bioreactor somehow recreate the natural situation experienced by 
the cells in the body better than in a standard 2D cell culture vessel. 
In conclusion, BR44 is a suitable MC for the cultivation of ASC52telo in a defined 
xeno- and serum-free medium. Regenerative applications require high biomass that 
should be obtained using a defined system. Now that we have suitable biodegradable 
MCs and a chemically defined medium for human ASCs, we are ready to check whether 
we can reproduce these results with primary human cells. Furthermore, the UrSuppe me-
dium could help study ex vivo the biology in healthy and dysfunctional states of adipo-
cytes and their precursors in defined and controlled cell culture conditions. 
Supplementary Materials: The following are available online at www.mdpi.com/2076-
3417/11/3/925/s1, Figure S1: A pluriStrainer Mini 40 µm is used to separates micro carriers (MCs) 
from the nuclei; Figure S2: scanning electron microscopy (SEM) microphotographs to show the mor-
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phology of some commercial dry MCs; Figure S3: SEM images to show the morphology of ProN-
ectin-F MCs; Figure S4: SEM microphotographs to show the morphology of the MC were used as a 
negative control; Figure S5: Fluorescent microphotographs of the MCs after reaction with the CF633 
dye; Figure S6: SEM microphotographs of the carrier BR44 after four days in culture without cells; 
Figure S7: DAPI stained samples of ASCs52Telo cultured on the prototype MC BR44 and the com-
mercial MC ProNectin-F in static condition for two days; Figure S8: Analysis of nuclei released from 
the microcarrier-based culture of ASC52telo cells using 7-AAD and volumetric flow cytometry; Fig-
ure S9: L-Mimosine stops proliferating ASC52telo cells before the onset of DNA replication; Figure 
S10: Growth curve; Figure S11: Time-dependent profiles of cell densities in the Corning spinner 
flasks; Figure S12: Single-parameter histograms for fourescence activated cell sorting (FACS) anal-
ysis of known surface markers on AC52Telo cells cultured in serum-free conditions (UrSuppe) on 
standard 2D cell culture vessels or microcarriers BR44 (3D); Figure S13: FACS analysis of known 
surface markers on AC52Telo cells cultured in serum-free conditions (UrSuppe): Comparison be-
tween cells grown on classical cell culture vessels (2D) or microcarriers ProNectin-F (PNF); Figure 
S14: Comparing the adipokines secretion profile of ASC52telo cells. Table S1: Published case studies 
for culture systems for human cells based on dissolvable or biodegradable microcarriers; Table S2: 
Materials; Table S3: Reverse transcription detailed procedure; Table S4: Primer sequences; Table S5: 
RT-qPCR cycle conditions; Table S6: Overview of measured stemness maintenance genes; Table S7: 
Overview of measured differentiation regulators/markers; Table S8: Human adipokine array. 
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Latin and Greek Symbols 
Amn mmol/L Ammonium concentration 
Atteff % Attachment efficiency  
EF - Expansion factor  
Glc mmol/L Glucose concentration 
Lac mmol/L Lactate concentration 
Ns1u rpm Impeller speed at which the MCs are still in contact with the 
reactor bottom but none of the at rest (lower limit of Ns1) 
PDL - Population doubling level 
P/V W/m3 Specific power input 
qAmn pmol/cell/d Specific ammonium production rate (growth-dependent) 
qGlc pmol/cell/d Specific glucose consumption rate 
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qLac pmol/cell/d Specific lactate production rate (growth-dependent) 
td d Doubling time of cell population 
tl d Lag or cell adaption time 
XA cells/cm2 Cell concentration on planar growth surface 
Xmax cells/cm2 Maximum cell concentration on planar growth surface  
YLac/Glc mmol/mmol Lactate yield per glucose equivalent 
μ 1/d Specific cell growth rate 
μmax 1/d Maximum specific cell growth rate 
τnt mPa Local volume-weighted mean shear stress 
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